Latin America Hereditary Angioedema Therapeutics Market Size & Outlook

The hereditary angioedema therapeutics market in Latin America is expected to reach a projected revenue of US$ 400.3 million by 2030. A compound annual growth rate of 12.9% is expected of Latin America hereditary angioedema therapeutics market from 2024 to 2030.
Revenue, 2023 (US$M)
$171.0
Forecast, 2030 (US$M)
$400.3
CAGR, 2024 - 2030
12.9%
Report Coverage
Latin America

Latin America hereditary angioedema therapeutics market, 2018-2030 (US$M)

Latin

Related Markets

Latin America hereditary angioedema therapeutics market highlights

  • The Latin America hereditary angioedema therapeutics market generated a revenue of USD 171.0 million in 2023.
  • The market is expected to grow at a CAGR of 12.9% from 2024 to 2030.
  • In terms of segment, kallikrein inhibitor was the largest revenue generating treatment in 2023.
  • Kallikrein inhibitor is the most lucrative treatment segment registering the fastest growth during the forecast period.
  • Country-wise, Mexico is expected to register the highest CAGR from 2024 to 2030.


Latin America data book summary

Market revenue in 2023USD 171.0 million
Market revenue in 2030USD 400.3 million
Growth rate12.9% (CAGR from 2023 to 2030)
Largest segmentKallikrein inhibitor
Fastest growing segmentKallikrein inhibitor
Historical data covered2018 - 2022
Base year for estimation2023
Forecast period covered2024 - 2030
Quantitative unitsRevenue in USD million
Market segmentationC1-esterase inhibitor, Bradykinin B2 receptor antagonist, Kallikrein inhibitor, Others Treatment
Key market players worldwideBioCryst Pharmaceuticals Inc, Ionis Pharmaceuticals Inc, CSL Ltd, Adverum Biotechnologies Inc, KalVista Pharmaceuticals Inc, Takeda Pharmaceutical Co Ltd, Pharming Group, Attune Pharmaceuticals


Other key industry trends

  • In terms of revenue, Latin America region accounted for 6.2% of the global hereditary angioedema therapeutics market in 2023.
  • Globally, North America is projected to lead the regional market in terms of revenue in 2030.
  • Asia Pacific is the fastest growing regional market and is projected to reach USD 1,494.8 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Hereditary Angioedema Therapeutics Market Scope

Hereditary angioedema therapeutics market segmentation & scope
C1-esterase inhibitor
Bradykinin B2 receptor antagonist
Kallikrein inhibitor
Others Treatment
Prophylaxis
On-demand
Intravenous
Subcutaneous
Oral

Hereditary Angioedema Therapeutics Market Companies

Name Profile # Employees HQ Website

Latin America hereditary angioedema therapeutics market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hereditary angioedema therapeutics market will help companies and investors design strategic landscapes.


Kallikrein inhibitor was the largest segment with a revenue share of 44.97% in 2023. Horizon Databook has segmented the Latin America hereditary angioedema therapeutics market based on c1-esterase inhibitor, bradykinin b2 receptor antagonist, kallikrein inhibitor, others treatment covering the revenue growth of each sub-segment from 2018 to 2030.


The Latin America hereditary angioedema therapeutics market exhibited significant growth in the past few years owing to high disease burden and increased demand for HAE drugs. Mexico, Brazil, and Argentina are prominent countries in the region, with Argentina having the highest percentage of diagnosed patients in Latin America.

Favorable government initiatives and research collaborations are anticipated to contribute to the market growth. In addition, the demand for drugs increased owing to current disease burden and high demand from healthcare providers.

Moreover, increasing R&D activities, coupled with rapid technological advancements in the region, are anticipated to fuel the market. Increasing government spending, growing investments by major pharmaceutical & biopharmaceutical companies, and the presence of major academic research institutes are factors likely to promote market growth.

Reasons to subscribe to Latin America hereditary angioedema therapeutics market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Latin America hereditary angioedema therapeutics market databook

  • Our clientele includes a mix of hereditary angioedema therapeutics market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of continent-level data and insights on the Latin America hereditary angioedema therapeutics market, including forecasts for subscribers. This continent databook contains high-level insights into Latin America hereditary angioedema therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Latin America hereditary angioedema hae therapeutics market size, by country, 2018-2030 (US$M)

Latin America Hereditary Angioedema Therapeutics Market Share, 2023 & 2030 (US$M)

Latin America hereditary angioedema hae therapeutics market size, by country, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more